Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration.

Zottel, Alja; Jovcevska, Ivana; Samec, Neja; Mlakar, Jernej; Sribar, Jernej; Krizaj, Igor; Skoblar Vidmar, Marija; Komel, Radovan

Zottel, Alja; Jovcevska, Ivana; Samec, Neja; Mlakar, Jernej; Sribar, Jernej; Krizaj, Igor; Skoblar Vidmar, Marija; Komel, Radovan.

Afiliação

Zottel A; Medical Centre for Molecular Biology, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Jovcevska I; Medical Centre for Molecular Biology, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Samec N; Medical Centre for Molecular Biology, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Mlakar J; Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Sribar J; Department of Molecular and Biomedical Sciences, Jozef Stefan Institute, Ljubljana, Slovenia.
Krizaj I; Department of Molecular and Biomedical Sciences, Jozef Stefan Institute, Ljubljana, Slovenia.
Skoblar Vidmar M; Department of Radiotherapy, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Komel R; Medical Centre for Molecular Biology, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000, Ljubljana, Slovenia.

Ther Adv Med Oncol ; 12: 1758835920915302, 2020.

Article em En | MEDLINE | ID: mdl-32426045

Palavras-chave

DPYSL2; NAP1L1; TUFM; cell migration; cytotoxicity; glioblastoma; glioblastoma stem cells; nanobodies; vimentin

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Eslovênia